Klebsiella pneumoniae

New England Journal of Medicine Publishes Positive Results of Cefepime-Taniborbactam from Phase 3 CERTAIN-1 Study of Patients with Complicated Urinary Tract Infection

Retrieved on: 
Tuesday, February 20, 2024

Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), including those with bacteremia.

Key Points: 
  • Venatorx Pharmaceuticals, Melinta Therapeutics LLC (“Melinta”), and Menarini Group today announced that The New England Journal of Medicine (NEJM) published the results of the CERTAIN-1 Phase 3 clinical study of the investigational agent cefepime-taniborbactam for the treatment of adult patients with complicated urinary tract infections (cUTI) and acute pyelonephritis (AP), including those with bacteremia.
  • The results showed that cefepime-taniborbactam was superior to meropenem for the treatment of complicated UTI that included acute pyelonephritis, with a similar safety profile to meropenem.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240220917017/en/
    “Gram-negative infections such as cUTI have become increasingly difficult to treat due to acquired bacterial resistance to multiple classes of antibiotics.

LG'S HOME LIFESTYLE SOLUTIONS PRESENT COMFORT AND CONVENIENCE AT KBIS 2024

Retrieved on: 
Friday, February 23, 2024

SEOUL, South Korea, Feb. 23, 2024 /PRNewswire/ -- LG Electronics (LG) is unveiling a range of home lifestyle solutions at the 2024 Kitchen & Bath Industry Show (KBIS) in Las Vegas, USA, from February 27-29. The company's latest innovations, including the bath solution, PuriCare™ HydroTower and system ironing, use sophisticated technologies and user-friendly design to elevate and enrich daily living.

Key Points: 
  • LG is expanding enhanced customer experience to the bathroom, one of the main living spaces in the home, by presenting a bath solution that provides convenience and comfort.
  • For greater comfort in the shower, LG's Smart Bath and Shower Purifier leverages thermostatics to maintain the selected water temperature.
  • Making its international debut at KBIS 2024, the HydroTower was successfully launched in South Korea last year, where it surpassed 10,000 units sold in only 50 days.
  • LG's new home solutions will be on display at the company's exhibition booth (West Hall #2343, Las Vegas Convention Center) during KBIS 2024 in Las Vegas, Nevada.

Basilea announces acquisition of preclinical antibiotics program from Spexis

Retrieved on: 
Monday, January 15, 2024

We are excited by the addition of this new program to our growing pipeline and to continue the development of this targeted antibiotics class, which has the potential to address an unmet medical need in the treatment of severe bacterial infections in the hospital.”

Key Points: 
  • We are excited by the addition of this new program to our growing pipeline and to continue the development of this targeted antibiotics class, which has the potential to address an unmet medical need in the treatment of severe bacterial infections in the hospital.”
    The antibiotics were developed within Spexis’ Outer Membrane Protein Targeting Antibiotics (OMPTA) program and selectively disrupt the lipopolysaccharide transport bridge, an essential structure in Gram-negative bacteria.
  • This results in a loss of the integrity of the outer cell membrane, intracellular accumulation of lipopolysaccharides and killing of the bacteria.
  • The program was funded in part by CARB-X (Combating Antibiotic-Resistant Bacteria Biopharmaceutical Accelerator).2 This underscores the potential of this novel class of antibiotics.
  • In addition, Basilea assumes the rights and obligations of Spexis, including potential low single-digit percentage royalties on sales, under licensing agreements.

EFE Introduces a Fresh Take on Reading Glasses with Quantum Technology- A Stylish Leap Forward for Vision and Comfort

Retrieved on: 
Tuesday, January 2, 2024

Blending the classic functionality of traditional reading glasses with the groundbreaking advancements of quantum technology, we are delivering an exceptional visual experience to our users.

Key Points: 
  • Blending the classic functionality of traditional reading glasses with the groundbreaking advancements of quantum technology, we are delivering an exceptional visual experience to our users.
  • We have expertly combined the usefulness of conventional reading glasses with the innovative capabilities of quantum technology.
  • This fusion offers an enhanced visual experience, taking a important leap forward for vision and comfort.
  • A Touch of Beauty in Every Look- In addition to being savvy, EFE reading glasses also care about appearance!

EFE Introduces Quantum Glasses: Pioneering the Future of Eyewear

Retrieved on: 
Saturday, December 16, 2023

New York, Dec. 15, 2023 (GLOBE NEWSWIRE) -- In a landmark innovation, EFE, the renowned eyewear brand from the Netherlands, proudly announces the launch of Quantum Glasses .

Key Points: 
  • New York, Dec. 15, 2023 (GLOBE NEWSWIRE) -- In a landmark innovation, EFE, the renowned eyewear brand from the Netherlands, proudly announces the launch of Quantum Glasses .
  • Crafted to meet the growing challenges of the digital era, Quantum Glasses represent a monumental leap in eyewear technology, offering unprecedented protection and enhancement for eyes frequently exposed to digital screens.
  • Quantum Glasses are a revolutionary product designed to combat the adverse effects of prolonged exposure to digital screens.
  • Unlike traditional blue light-blocking glasses, these glasses incorporate advanced features that go beyond simply alleviating digital eye strain.

Recce Pharmaceuticals Granted New Patent in Canada for RECCE® Anti-Infectives

Retrieved on: 
Monday, November 27, 2023

SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.

Key Points: 
  • SYDNEY, Australia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Recce Pharmaceuticals Limited (ASX: RCE, FSE: R9Q), the Company developing a new class of synthetic anti-infectives, is pleased to announce the Canadian Patent Office has formally granted Recce a new family four patent, “Process for Preparation of Biologically Active Copolymer,” with expiry in 2041.
  • “We thank the Canadian Government for their recognition of the significant potential of Recce’s New Class of Anti-infectives,” said James Graham, Chief Executive Officer of Recce Pharmaceuticals.
  • In July 2023, the Company received an AUD $98,428 R&D Rebate from the Canadian Government, under the Scientific Research & Experimental Development (SR&ED) Tax Incentive program.
  • The program is administered by the Canada Revenue Agency and is aimed at incentivizing businesses to conduct R&D in Canada, encouraging innovation and technological advancements.

Jemincare Announces 6 Approvals of Clinical Trials for its Innovative Drugs

Retrieved on: 
Tuesday, December 26, 2023

On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria.

Key Points: 
  • On December 20, NMPA has approved a clinical trial for JMKX003801 to treat serious infection caused by Gram-negative bacteria.
  • Drug resistance of antibiotics, especially carbapenem resistance, in Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa has risen year by year.
  • On December 12, NMPA has approved a clinical trial for JMKX003142 to treat renal edema.
  • On December 12, FDA has approved a clinical trial for JMKX000197 to treat BCG-unresponsive non-muscle-invasive bladder cancer, and earlier on October 19, NMPA has approved the clinical trial.

PHAXIAM Provides Business and Financial Update for the Third Quarter of 2023

Retrieved on: 
Tuesday, November 14, 2023

The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.

Key Points: 
  • The enrollment is targeted to start by the end of 2023 and the first study results are expected in mid-2024.
  • Key financial figures for the first nine months of 2023 compared with the same period of the previous year are summarized below.
  • In the context of the Erytech-Pherecydes merger, PHAXIAM’s consolidated financial statements in IFRS standards include ex-Pherecydes financial results as from the date of the merger, i.e.
  • Consequently, PHAXIAM’s P&L information for the first 9 months of 2023 include 9 months of ex-Erytech activities and ex-Pherecydes activities since June 23, 2023.

Glox Therapeutics Secures £4.3M Seed Funding to Develop Precision Antimicrobials Targeting Drug-resistant Bacteria

Retrieved on: 
Tuesday, November 14, 2023

Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.

Key Points: 
  • Glox Therapeutics, a company pioneering the development of precision antibiotic therapies based on naturally occurring bacteriocins, today announced it has raised £4.3M in seed funding to develop effective targeted therapeutics against antibiotic-resistant Gram-negative bacteria.
  • **
    Glox Therapeutics is developing precision antibiotics utilising engineered protein bacteriocins.
  • Leveraging the power of bacteriocins, Glox Therapeutics aims to advance the field of antimicrobial therapy by overcoming resistance to traditional antibiotics.
  • “This seed funding is testament to the promise of Glox Therapeutics’ precise antibiotic therapies, and we are thrilled to have the backing of such high-calibre investors.

ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical Study

Retrieved on: 
Monday, October 16, 2023

“We are very pleased with the FDA’s clearance of our IND application for CF-370.

Key Points: 
  • “We are very pleased with the FDA’s clearance of our IND application for CF-370.
  • HABP/VABP occurs in patients in hospitals or other health care facilities and can be caused by a variety of bacteria.
  • P. aeruginosa, Acinetobacter species, Klebsiella species, E. coli and Enterobacter species are the most commonly implicated Gram-negative pathogens in HABP/VABP infections.
  • The HAI Progress Report includes data from 3,917 facilities reporting to the National Healthcare Safety Network covering 36.3 million hospital admissions.